摘要/Abstract

摘要： 乳腺癌是女性发病率最高的恶性肿瘤，10%~20%的晚期乳腺癌患者会发生脑转移。近年来随着系统治疗的快速发展，乳腺癌颅外病灶得以有效控制，患者的生存期得以延长，而发生脑转移的可能性也在增加；影像学技术的进步以及常规影像学监测的普及也增加了颅内病灶的检出率。这些都使得乳腺癌脑转移在临床上越来越常见。许多化学治疗药物不能透过血脑屏障。对于发生脑转移的患者，其可选择的治疗方法较少，生存期较短并且生活质量较低。该文着重阐述近年来乳腺癌脑转移系统治疗的研究进展，旨在为该类疾病的基础研究和临床实践提供参考。
关键词: 乳腺癌, 脑转移, 系统治疗, 人表皮生长因子受体2, 靶向治疗
Abstract:
Breast cancer is one of the most common malignancies in women. Brain metastases occur in approximately 10%–20% of patients with advanced breast cancer. In recent years, with the rapid progress of systemic treatment, extracranial lesions have been effectively controlled and the survival time of patients with breast cancer have been prolonged. Thus the possibility of developing brain metastases has been increased. Moreover, advances in modern diagnostic imaging technology and the routine surveillance of cancer patients have increased the detection rate of brain lesions. Based on the above two aspects, the breast cancer brain metastases (BCBM) have become increasingly common in the clinical settings. Because many chemotherapeutic drugs can not penetrate the blood-brain barrier, the patients with brain metastases have less treatment options, worse survival outcomes and lower quality of life. This article focuses on the recent advances in systemic treatment for BCBM, aiming to provide reference for basic research and clinical practices of this disease.
Key words: breast cancer, brain metastasis, systemic therapy, human epidermal growth factor receptor 2 (HER2), targeted therapy


PDF全文下载地址:

点我下载PDF